NICE Recommends Vimizim For Treating MPS IVA Morquio

Apr 29, 2022 | Clinical Trials, News, Research, Treatment

We are excited to hear that Elosulfase alfa – branded as Vimizin and made by BioMarin – has been recommended by NICE (National Institute for Health and Care Excellence) for treating MPS IVA Morquio in England and Wales. Newly diagnosed patients and those already receiving treatment will be able to access this therapy.

Elosulfase alfa is now the first disease modifying treatment recommended by NICE for routine use in England for people with this rare, severely life-limiting condition. This recommendation and continued access to the treatment will give hope to people with MPS IVA, their families and carers of a better future. 

Read the full press release >>